Explore
Updates on Molecular Targeted Therapies for CNS Tumors
Edward Pan (editor)
2023
0 Ungluers have
Faved this Work
Login to Fave
The challenges in identifying effective therapies for CNS tumors continue to be daunting. Potentially effective targeted therapies must be able to penetrate the blood–brain barrier to reach the tumor and, in sufficient concentrations, to result in meaningful treatment responses. Moreover, molecular targets must be key drivers in the growth and progression of CNS tumors. Numerous potentially efficacious therapies have failed in randomized clinical trials due to other factors, including subclonal genetic intratumoral heterogeneity (particularly within malignant gliomas), epigenetic heterogeneity, and failure to target important factors involved in the tumor microenvironment. Developing effective targeted therapies requires a thorough fundamental understanding of the genetic and epigenetic factors driving tumor progression, the interactions between CNS tumor cells and the tumor microenvironment, and the key mechanisms of tumor treatment resistance. In this Special Issue, experts in the field of CNS tumors will highlight the most promising molecular targets in the development of treatments for patients with CNS tumors.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 38 times via unglue.it ebook links.
- 38 - pdf (CC BY) at Unglue.it.
Keywords
- A172
- A2AAR antagonist
- Adenosine
- adenosine receptors
- antigen processing and presentation
- antioxidant
- Apoptosis
- ATRX
- bevacizumab
- biomarker
- blood–brain barrier
- brain metastasis
- brain tumor
- Cancer Metabolism
- cell cycle arrest
- Central nervous system
- chemotherapy
- Clinical & internal medicine
- CNS disease
- CNS lymphoma
- CpG island
- diffuse midline gliomas
- Diseases & disorders
- DNMT
- EGFR
- ependymoma
- EPHB2
- epidermal growth factor receptor
- ERK/MAPK pathway
- FGFR3
- G-CIMP
- GBM
- germline mutation
- Glioblastoma
- glioblastoma molecular classification
- Glioma
- Group A
- Group B
- H3K27M
- histone acetylation
- IDH-mutant glioma
- Immune Evasion
- immune score
- Immunotherapy
- intraparenchymal metastases
- intrathecal
- isotope labeling
- KIF11
- leptomeningeal
- low grade glioma
- low-grade glioma
- LPS
- lung cancer
- lung carcinoma
- lung malignancy
- Mass Spectrometry
- medicine
- meningitis
- Met
- metastatic disease
- metformin
- methotrexate
- Methylation
- methylomics
- Methyltransferases
- MGMT
- molecular targets
- molecular therapy
- monoclonal antibodies
- MYCN
- myxopapillary
- n/a
- neoantigen
- neoplastic
- Neurofibromatosis
- NF1
- novel therapeutics
- novel therapies
- oncology
- patient avatars
- PCNSL
- PDGFRA
- pediatric brain tumor
- PFA
- PFB
- PI3K/PTEN pathway
- plexiform neurofibroma
- potential therapy development
- preclinical models
- progression
- progression-free survival
- Radiotherapy
- receptor tyrosine kinase
- Rela
- Stereotactic radiosurgery
- subependymoma
- T cells
- T lymphocytes
- targeted therapy
- temozolomide
- Tumor microenvironment
- tumor mutation burden
- tumor suppressor
- Tyrosine kinase inhibitors
- U87MG
- vestibular schwannoma
- Warburg effect
- whole-brain radiation therapy
- YAP1
- ZFTA
Links
DOI: 10.3390/books978-3-0365-8529-1Editions